Morgan Stanley Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price

Posted by Trevor Kearing on Feb 5th, 2026

Amgen (NASDAQ:AMGN – Free Report) had its target price lifted by Morgan Stanley from $304.00 to $309.00 in a report released on Wednesday morning, MarketBeat Ratings reports. They currently have an equal weight rating on the medical research company’s stock.

Other analysts have also issued research reports about the stock. BMO Capital Markets raised their price target on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Piper Sandler upped their price target on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, December 15th. Finally, UBS Group lifted their price objective on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average target price of $347.65.

Get Our Latest Research Report on Amgen

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $366.22 on Wednesday. The business has a fifty day moving average of $333.19 and a 200-day moving average of $310.44. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. Amgen has a twelve month low of $261.43 and a twelve month high of $368.75. The firm has a market cap of $197.20 billion, a PE ratio of 25.74, a price-to-earnings-growth ratio of 2.98 and a beta of 0.46.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 152.71%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.8%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 73.57%.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,908 shares of company stock valued at $3,674,966 over the last three months. 0.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amgen

Several institutional investors have recently modified their holdings of the business. Laurel Wealth Advisors LLC grew its position in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares during the period. Norges Bank acquired a new position in shares of Amgen in the second quarter valued at approximately $1,663,726,000. Capital World Investors increased its position in shares of Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. Finally, National Bank of Canada FI raised its holdings in shares of Amgen by 237.7% during the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after acquiring an additional 863,216 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Q4 results beat and company guidance lifted — Amgen reported Q4 EPS and revenue above Street estimates and issued FY‑2026 EPS and revenue guidance that came in around expectations while signaling continued product-volume growth; this is the primary catalyst pushing the stock higher. Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Positive Sentiment: Goldman Sachs raised its price target to $415 and kept a Buy rating — a high-profile upward revision that signals confidence in Amgen’s growth runway and likely supports further buying interest. Goldman Sachs adjusts price target on Amgen to $415 from $403, maintains Buy
Positive Sentiment: Portfolio & pipeline momentum — coverage notes highlight double‑digit revenue and EPS growth for 2025 and faster uptake of new Amgen products (including obesity assets) that underpin the company’s guidance and longer‑term upside. Amgen posts double-digit revenue and EPS growth for 2025
Positive Sentiment: Obesity program and late‑stage data in focus — investors are increasingly oriented toward MariTide/MariTide‑related obesity studies and other pipeline catalysts that could materially add revenue, helping explain enthusiastic flows. AMGN’s Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
Positive Sentiment: Technical/institutional signal — the stock is trading near 52‑week highs and commentary suggests heavy institutional buying, reinforcing momentum into today’s session. Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
Neutral Sentiment: Cantor Fitzgerald raised its price target to $350 but kept a Neutral rating — PT higher but rating unchanged, so limited directional push from this call. Amgen (AMGN) PT Raised to $350 at Cantor Fitzgerald
Neutral Sentiment: Morgan Stanley nudged its target to $309 but kept an Equal‑Weight rating — the firm raised its view slightly but still implies downside vs. the current price, so the call is not uniformly bullish. Morgan Stanley raises price target on Amgen to $309 from $304, keeps Equal-Weight
Negative Sentiment: Analysts flag execution/legacy‑product risks — some coverage (Citi and others) notes legacy product erosion and execution risks that could temper upside if new products don’t scale as expected. That is the key watch‑out for investors despite today’s positive headlines. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks

About Amgen

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.